EPIENDO PHARMACEUTICALS

EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity as a causal pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human skin and lung tissue, as well as the intestinal tract and genitalia. Compromised integrity of this barrier is implicated in the progression and non-resolution of inflam... mation. EpiEndo is developing a proprietary portfolio of orally available macrolide drug candidates with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic respiratory diseases and other significant unmet medical needs. EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, disease modifying, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for COPD and other inflammatory airway diseases.

#SimilarOrganizations #People #Financial #Event #Website #More

EPIENDO PHARMACEUTICALS

Social Links:

Facebook

Twitter

Industry:

Biotechnology Health Care Medical

Founded:

2014-01-01

Address:

Reykjavík, Gullbringusysla, Iceland

Country:

Iceland

Website Url:

http://www.epiendo.com

Total Employee:

Status:

Active

Contact:

00 354 454 0090

Email Addresses:

[email protected]

Total Funding:

33.33 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Euro Microsoft Exchange Online Organization Schema Microsoft Azure DNS